Bil­lions on the line, No­var­tis and Am­gen ex­change broad­sides as Aimovig part­ner­ship erupts in­to a le­gal war

No­var­tis has had noth­ing but up­beat things to say about their hot new mi­graine drug Aimovig and the reengi­neered col­lab­o­ra­tion pact with Am­gen back in 2017 that gave them half of the lu­cra­tive US mar­ket.

Un­til to­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER